论文部分内容阅读
目的:研究肾综合征出血热疫苗效果免疫(感染)增强和免疫策略。方法:在疫苗试区设立对照组和接种组,观察期为1995年8月至1998年12月,全程接种3针,1年后加强1针。结果:全程接种了10178人,对照人群全程观察16159人,当年发病减少数为33例,4年平均保护率达93.89％。人群接种后局部和全身反应较明显。全程接种后2周荧光(IFA)抗体和中和抗体阳转率分别为100％和44.44％,一年后分别下降到28.57％和14.80％;加强后2周IFA抗体和中和抗体阳转率分别反弹至83.33％和55.56％,其抗体几何平均滴度(GMT)也随之下降和回升。结论:疫苗是安全有效的,有较好的血清学效果和流行病学效果,有免疫增强反应,但未发现感染增强反应。此外,加强免疫很有必要。
Objective: To study the immunization (infection) enhancement and immunization strategy of hemorrhagic fever with renal syndrome. Methods: The control group and vaccination group were set up in the vaccine trial area. The observation period was from August 1995 to December 1998 with 3 doses in total and 1 dose in 1 year. Results: 10,178 people were inoculated in the whole process and 16,159 people were observed in the control group. The number of cases reduced in the year was 33 and the average protection rate in 4 years was 93.89%. Local and systemic reactions after vaccination are more pronounced. After 2 weeks of inoculation, the positive rates of IFA antibody and neutralizing antibody were 100% and 44.44%, respectively, and decreased to 28.57% and 14.80% respectively one week later. IFA antibody and neutralization antibody positive rate Respectively rebounded to 83.33% and 55.56%, the antibody geometric mean titer (GMT) also decreased and rebounded. Conclusion: The vaccine is safe and effective, has good serological and epidemiological effects, and has immune-enhancing response, but no enhanced infection response was found. In addition, it is necessary to strengthen immunity.